论文信息 - Study CTKI258A2202: A multicenter, open-label phase II trial of dovitinib (TKI258) in FGFR1-amplified and nonamplified HER2-negative metastatic breast cancer. - 字舞流文

Study CTKI258A2202: A multicenter, open-label phase II trial of dovitinib (TKI258) in FGFR1-amplified and nonamplified HER2-negative metastatic breast cancer.

M. Ellis | J. Baselga | H. Rugo | F. André | M. Shi | N. Turner | S. Hurvitz | O. Anak | E. Argonza-Aviles | S. Lake